.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Consequently, GSK recently announced its acquisition of 35Pharma to advance a promising GSK pulmonary hypertension drug candidate. This $950 million cash deal represents the second major move by new CEO Luke Miels. Specifically, the acquisition focuses on HS235, an experimental therapy designed to treat pulmonary hypertension. This condition currently affects over 80 million people globally and remains a life-shortening disease. Therefore, medical professionals closely watch these developments in the respiratory pipeline.
Furthermore, HS235 targets patients who suffer from obesity and a specific type of heart condition. Early studies on obese mice with preserved ejection fraction showed that the drug effectively reduced fat mass. Notably, it also boosted heart function during these preclinical trials. Additionally, researchers believe that if clinical trials succeed, patients might only require an injection every four weeks. This reduced dosing frequency could significantly improve patient compliance and quality of life.
Simultaneously, Miels aims to counter looming patent expiries for GSK's top-selling HIV medications. This deal follows a $2.2 billion acquisition of RAPT Therapeutics earlier this year. Moreover, GSK secured global rights to kidney disease therapies from Frontier Biotechnologies just this week. These strategic bolt-on deals reflect a broader shift toward specialized therapeutic areas. Consequently, the company avoids the increasingly crowded general obesity treatment market. Instead, GSK prioritizes the downstream effects of obesity, such as liver and heart diseases.
Q1: What is the primary target of the drug HS235?
HS235 targets pulmonary hypertension, specifically in patients with obesity and heart conditions like preserved ejection fraction.
Q2: How often would patients receive the HS235 injection if approved?
Clinical trials suggest the injectable drug could be administered once every four weeks or potentially even less frequently.
Q3: Why is GSK focusing on niche obesity-related diseases?
The company seeks to avoid the crowded general obesity market by focusing on downstream effects like liver, heart, and respiratory issues.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
GSK buys 35Pharma for $950M to acquire HS235, an experimental pulmonary hypertension drug targeting patients with heart conditions and obesity....
4 months ago
A parliamentary panel has urged the FSSAI to finalise front-of-pack nutrition labelling regulations without further delay. The committee stressed that simple, color-coded indicators for sugar and clear warning labels are vital to combat dietary non-communicable diseases and guide informed consumer choices.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
Today
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
Today
A parliamentary standing committee has directed FSSAI to expedite front-of-pack nutrition labelling regulations. The panel highlighted that over two years of delay since the 2022 draft notification leaves consumers relying on complex numerical labels, urging simple color-coded sugar indicators and warnings.
Today
